Specifically, mediation classes such as angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor antagonists (ARB), and sodium-glucose cotransporter 2 (SGLT2) inhibitors can have a beneficial impact on the progression of kidney disease. The gene discussed is SLC5A2; the disease is kidney disorder.